(Q33523171)

27 July 2017

title

Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan (English)

1 reference

cost-effectiveness analysis

27 July 2017

main subject

1 reference

inferred from title

cervix uterine cancer

1 reference

Pang-Hsiang Liu

1

0 references

Ping-Ing Lee

object named as

Ping-Ing Lee

3

0 references

author name string

Fu-Chang Hu

2

1 reference

27 July 2017

Song-Nan Chow

4

1 reference

27 July 2017

Chao-Wan Huang

5

1 reference

27 July 2017

Jung-Der Wang

6

1 reference

27 July 2017

publication date

11 January 2010

1 reference

BMC Health Services Research

27 July 2017

published in

1 reference

27 July 2017

volume

10

1 reference

27 July 2017

page(s)

11

1 reference

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

27 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822833

Economic evaluations of massive HPV vaccination: within-study and between study variations in incremental cost per QALY gained.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822833

Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822833

Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822833

Epidemiology of human papillomavirus infection and cervical cancer and future perspectives in Hong Kong, Singapore and Taiwan

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822833

Health and economic implications of HPV vaccination in the United States

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822833

Economic evaluation of human papillomavirus vaccination in the United Kingdom

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822833

Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822833

Cost-effectiveness of human papillomavirus vaccination in the United States

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822833

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822833

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822833

Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822833

Cost-effectiveness analyses of human papillomavirus vaccination

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822833

Model for assessing human papillomavirus vaccination strategies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822833

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822833

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822833

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822833

Evaluating human papillomavirus vaccination programs

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822833

Cost-effectiveness of a potential vaccine for human papillomavirus

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822833

Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822833

Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822833

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822833

Rapidly progressive cervical cancer: the Connecticut experience

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822833

Natural history of cervical intraepithelial neoplasia: a critical review.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822833

Outpatient excisional management of cervical intraepithelial neoplasia. A prospective, randomized comparison between loop diathermy excision and laser excisional conization

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822833

Human papillomavirus testing in primary cervical screening.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822833

Meta-analysis of Pap test accuracy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822833

High prevalence of genital human papillomavirus type 52 and 58 infection in women attending gynecologic practitioners in South Taiwan.

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-10-11

Cervical cancer screening program integrating Pap smear and HPV DNA testing: a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-10-11

Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-10-11

A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-10-11

Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-10-11

Markov models in medical decision making: a practical guide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-10-11

The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-10-11

Natural history of cervicovaginal papillomavirus infection in young women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-10-11

The distribution and differential risks of human papillomavirus genotypes in cervical preinvasive lesions: A Taiwan Cooperative Oncologic Group Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-10-11

Natural history of cervical squamous intraepithelial lesions: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-10-11

Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-10-11

Cervical intraepithelial neoplasia in women infected with the human immunodeficiency virus: outcome after loop electrosurgical excision

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-10-11

Epidemiologic Evidence and Human Papillomavirus Infection as a Necessary Cause of Cervical Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-10-11

Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-10-11

Epidemiology of Acquisition and Clearance of Cervical Human Papillomavirus Infection in Women from a High‐Risk Area for Cervical Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-10-11

Costs of cervical cancer and precancerous lesions treatment in a publicly financed health care system

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822833

The natural history of human papillomavirus infection and cervical intraepithelial neoplasia among young women in the Guanacaste cohort shortly after initiation of sexual life.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822833

Efficacy and cost-effectiveness of nationwide cervical cancer screening in Taiwan.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822833

Prevalence of cervical human papillomavirus in Taiwanese women.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822833

Type-specific distribution of HPV along the full spectrum of cervical carcinogenesis in Taiwan: an indication of viral oncogenic potential

31 October 2018

1 reference

12 December 2020

The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada

1 reference

12 December 2020

The screening histories of women with invasive cervical cancer, Connecticut

1 reference

12 December 2020

Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions

1 reference

12 December 2020

Natural history of dysplasia of the uterine cervix

1 reference

12 December 2020

Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France

1 reference

12 December 2020

The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan

1 reference

12 December 2020

Economic evaluation of vaccination programs: the impact of herd-immunity

1 reference

12 December 2020

Persistence of type-specific human papillomavirus infection among cytologically normal women

1 reference

12 December 2020

Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear

1 reference

12 December 2020

Human papillomavirus types 52 and 58 are prevalent in cervical cancer from Chinese women

1 reference

12 December 2020

Human papillomavirus and cervical neoplasia: a case-control study in Taiwan

1 reference

12 December 2020

Cost-utility analysis of vaccination against HPV in Israel.

1 reference

12 December 2020

Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica

1 reference

12 December 2020

Identifiers

DOI

10.1186/1472-6963-10-11

1 reference

Dimensions Publication ID

27 July 2017

0 references

1 reference

27 July 2017

1 reference